Recent developments with live-attenuated recombinant paramyxovirus vaccines

Reviews in Medical Virology

Volumn 23, Issue 1, 2013, Pages 15-34

  Bayon, Jean Christophe Le ^a,b   Lina, Bruno ^a,c   Rosa Calatrava, Manuel ^a   Boivin, Guy ^b  

^a UNIVERSITÉ LYON 1   (France)

^b LAVAL UNIVERSITY   (Canada)

^c HOSPICES CIVILS DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PARAMYXOVIRUS VACCINE; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

ANTIBODY TITER; COST EFFECTIVENESS ANALYSIS; GENE DELETION; HEALTH PROGRAM; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LIPID BILAYER; NONHUMAN; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW;

ANIMALS; HUMANS; RESPIROVIRUS; RESPIROVIRUS INFECTIONS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL PROTEINS; VIRAL VACCINES;

EID: 84872317571     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1717     Document Type: Review

References (157)

1. Lamb RA, Parks GD. Paramyxoviridae: the viruses and their replication. In Fields Virology Fifth ed, Knipe DM, Howley PM (eds). Philadelphia, 2007; 1449-1496.
2. Collins PL, Crowe JE. Respiratory syncytial virus and metapneumovirus. In Fields Virology 5th Edition ed, Knipe DM, Howley PM (eds). Philadelphia, 2007; 1601-1646.
3. Karron RA, Collins PL. Parainfluenza viruses. In Fields Virology 5th Edition ed, Knipe DM, MHP (eds). Philadelphia, 2007; 1497-1526.
4. He B, Leser GP, Paterson RG, et al. The paramyxovirus SV5 small hydrophobic (SH) protein is not essential for virus growth in tissue culture cells. Virology 1998; 250: 30-40.
5. Feuillet F, Lina B, Rosa-Calatrava M, et al. Ten years of human metapneumovirus research. Journal of Clinical Virology 2012; 53: 97-105.
6. Bukreyev A, Whitehead SS, Murphy BR, et al. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. Journal of Virology 1997; 71: 8973-8982.
7. Whitehead SS, Bukreyev A, Teng MN, et al. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. Journal of Virology 1999; 73: 3438-3442.
8. Lin Y, Bright AC, Rothermel TA, et al. Induction of apoptosis by paramyxovirus simian virus 5 lacking a small hydrophobic gene. Journal of Virology 2003; 77: 3371-3383.
9. Wilson RL, Fuentes SM, Wang P, et al. Function of small hydrophobic proteins of paramyxovirus. Journal of Virology 2006; 80: 1700-1709.
10. Herfst S, Mas V, Ver LS, et al. Low-pH-induced membrane fusion mediated by human metapneumovirus F protein is a rare, strain-dependent phenomenon. Journal of Virology 2008; 82: 8891-8895.
11. Schowalter RM, Chang A, Robach JG, et al. Low-pH triggering of human metapneumovirus fusion: essential residues and importance in entry. Journal of Virology 2009; 83: 1511-1522.
12. Tayyari F, Marchant D, Moraes TJ, et al. Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nature Medicine 2011; 17: 1132-1135.
13. Cseke G, Maginnis MS, Cox RG, et al. Integrin alphavbeta1 promotes infection by human metapneumovirus. Proceedings of the National Academy of Sciences of the United States of America 2009; 106: 1566-1571.
14. Chang A, Masante C, Buchholz UJ, et al. Human metapneumovirus (HMPV) binding and infection are mediated by interactions between the HMPV fusion protein and heparan sulfate. Journal of Virology 2012; 86: 3230-3243.
15. Teng MN, Whitehead SS, Collins PL. Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology 2001; 289: 283-296.
16. Yin HS, Wen X, Paterson RG, et al. Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature 2006; 439: 38-44.
17. Zimmer G, Conzelmann KK, Herrler G. Cleavage at the furin consensus sequence RAR/KR(109) and presence of the intervening peptide of the respiratory syncytial virus fusion protein are dispensable for virus replication in cell culture. Journal of Virology 2002; 76: 9218-9224.
18. Russell CJ, Luque LE. The structural basis of paramyxovirus invasion. Trends in Microbiology 2006; 14: 243-246.
19. Connolly SA, Leser GP, Jardetzky TS, et al. Bimolecular complementation of paramyxovirus fusion and hemagglutinin-neuraminidase proteins enhances fusion: implications for the mechanism of fusion triggering. Journal of Virology 2009; 83: 10857-10868.
20. Takimoto T, Taylor GL, Connaris HC, et al. Role of the hemagglutinin-neuraminidase protein in the mechanism of paramyxovirus-cell membrane fusion. Journal of Virology 2002; 76: 13028-13033.
21. Melanson VR, Iorio RM. Addition of N-glycans in the stalk of the Newcastle disease virus HN protein blocks its interaction with the F protein and prevents fusion. Journal of Virology 2006; 80: 623-633.
22. Tsurudome M, Ito M, Nishio M, et al. Hemagglutinin-neuraminidase-independent fusion activity of simian virus 5 fusion (F) protein: difference in conformation between fusogenic and nonfusogenic F proteins on the cell surface. Journal of Virology 2001; 75: 8999-9009.
23. Tsurudome M, Ito M, Nishio M, et al. Identification of regions on the fusion protein of human parainfluenza virus type 2 which are required for haemagglutinin-neuraminidase proteins to promote cell fusion. Journal of General Virology 1998; 79(Pt 2): 279-289.
24. Gardner AE, Martin KL, Dutch RE. A conserved region between the heptad repeats of paramyxovirus fusion proteins is critical for proper F protein folding. Biochemistry 2007; 46: 5094-5105.
25. Swanson K, Wen X, Leser GP, et al. Structure of the Newcastle disease virus F protein in the post-fusion conformation. Virology 2010; 402: 372-379.
26. Fearns R, Collins PL. Role of the M2-1 transcription antitermination protein of respiratory syncytial virus in sequential transcription. Journal of Virology 1999; 73: 5852-5864.
27. Schickli JH, Kaur J, Macphail M, et al. Deletion of human metapneumovirus M2-2 increases mutation frequency and attenuates growth in hamsters. Virology Journal 2008; 5: 69.
28. Bermingham A, Collins PL. The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proceedings of the National Academy of Sciences of the United States of America 1999; 96: 11259-11264.
29. Bossert B, Marozin S, Conzelmann KK. Nonstructural proteins NS1 and NS2 of bovine respiratory syncytial virus block activation of interferon regulatory factor 3. Journal of Virology 2003; 77: 8661-8668.
30. Spann KM, Tran KC, Chi B, et al. Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected]. Journal of Virology 2004; 78: 4363-4369.
31. Kotelkin A, Belyakov IM, Yang L, et al. The NS2 protein of human respiratory syncytial virus suppresses the cytotoxic T-cell response as a consequence of suppressing the type I interferon response. Journal of Virology 2006; 80: 5958-5967.
32. Stockman LJ, Curns AT, Anderson LJ, et al. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatric Infectious Disease Journal 2012; 31: 5-9.
33. Williams JV, Edwards KM, Weinberg GA, et al. Population-based incidence of human metapneumovirus infection among hospitalized children. Journal of Infectious Diseases 2010; 201: 1890-1898.
34. Cilla G, Onate E, Perez-Yarza EG, et al. Hospitalization rates for human metapneumovirus infection among 0- to 3-year-olds in Gipuzkoa (Basque Country), Spain. Epidemiology and Infection 2009; 137: 66-72.
35. Chiu SS, Chan KH, Chen H, et al. Virologically confirmed population-based burden of hospitalization caused by respiratory syncytial virus, adenovirus, and parainfluenza viruses in children in Hong Kong. Pediatric Infectious Disease Journal 2010; 29: 1088-1092.
36. Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. Journal of Pediatrics 2003; 143: S127-132.
37. Welliver RC. Respiratory syncytial virus and other respiratory viruses. Pediatric Infectious Disease Journal 2003; 22: S6-10; discussion S10-12.
38. Welliver RC, Wong DT, Sun M, et al. Parainfluenza virus bronchiolitis. Epidemiology and pathogenesis. American Journal of Diseases of Children 1986; 140: 34-40.
39. Henrickson KJ, Kuhn SM, Savatski LL. Epidemiology and cost of infection with human parainfluenza virus types 1 and 2 in young children. Clinical Infectious Diseases 1994; 18: 770-779.
40. Glezen WP, Frank AL, Taber LH, et al. Parainfluenza virus type 3: seasonality and risk of infection and reinfection in young children. Journal of Infectious Diseases 1984; 150: 851-857.
41. Boivin G, De Serres G, Cote S, et al. Human metapneumovirus infections in hospitalized children. Emerging Infectious Diseases 2003; 9: 634-640.
42. Paes BA, Mitchell I, Banerji A, et al. A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice. Canadian Respiratory Journal 2011; 18: e10-19.
43. Garcia CG, Bhore R, Soriano-Fallas A, et al. Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis. Pediatrics 2010; 126: e1453-1460.
44. Leader S, Yang H, Devincenzo J, et al. Time and out-of-pocket costs associated with respiratory syncytial virus hospitalization of infants. Value in Health 2003; 6: 100-106.
45. Marx A, Gary HE Jr., Marston BJ, et al. Parainfluenza virus infection among adults hospitalized for lower respiratory tract infection. Clinical Infectious Diseases 1999; 29: 134-140.
46. Glezen WP, Taber LH, Frank AL, et al. Risk of primary infection and reinfection with respiratory syncytial virus. American Journal of Diseases of Children 1986; 140: 543-546.
47. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. Journal of the American Medical Association 2003; 289: 179-186.
48. Hall CB, Douglas RG Jr., Geiman JM. Possible transmission by fomites of respiratory syncytial virus. Journal of Infectious Diseases 1980; 141: 98-102.
49. Lessler J, Reich NG, Brookmeyer R, et al. Incubation periods of acute respiratory viral infections: a systematic review. The Lancet Infectious Diseases 2009; 9: 291-300.
50. Liao S, Bao X, Liu T, et al. Role of retinoic acid inducible gene-I in human metapneumovirus-induced cellular signalling. Journal of General Virology 2008; 89: 1978-1986.
51. Bueno SM, Gonzalez PA, Riedel CA, et al. Local cytokine response upon respiratory syncytial virus infection. Immunology Letters 2011; 136: 122-129.
52. Laham FR, Israele V, Casellas JM, et al. Differential production of inflammatory cytokines in primary infection with human metapneumovirus and with other common respiratory viruses of infancy. Journal of Infectious Diseases 2004; 189: 2047-2056.
53. Skiadopoulos MH, Biacchesi S, Buchholz UJ, et al. Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity. Virology 2006; 345: 492-501.
54. Spriggs MK, Murphy BR, Prince GA, et al. Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity. Journal of Virology 1987; 61: 3416-3423.
55. Hussell T, Spender LC, Georgiou A, et al. Th1 and Th2 cytokine induction in pulmonary T cells during infection with respiratory syncytial virus. Journal of General Virology 1996; 77(Pt 10): 2447-2455.
56. Hussell T, Baldwin CJ, O'garra A, et al. CD8+ T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection. European Journal of Immunology 1997; 27: 3341-3349.
57. Krilov LR. Respiratory syncytial virus disease: update on treatment and prevention. Expert Review of Anti-Infective Therapy 2011; 9: 27-32.
58. Chakrabarti S, Collingham KE, Holder K, et al. Parainfluenza virus type 3 infections in hematopoetic stem cell transplant recipients: response to ribavirin therapy. Clinical Infectious Diseases 2000; 31: 1516-1518.
59. Nichols WG, Corey L, Gooley T, et al. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001; 98: 573-578.
60. Safdar A. Immune modulatory activity of ribavirin for serious human metapneumovirus disease: early i.v. therapy may improve outcomes in immunosuppressed SCT recipients. Bone Marrow Transplantation 2008; 41: 707-708.
61. Wyde PR, Chetty SN, Jewell AM, et al. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Research 2003; 60: 51-59.
62. Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. Journal of Infectious Diseases 1997; 176: 1215-1224.
63. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. Journal of Pediatrics 2003; 143: 532-540.
64. Meissner HC, Long SS. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003; 112: 1447-1452.
65. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531-537.
66. Wang D, Bayliss S, Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. Health Technology Assessment 2011; 15: iii-iv, 1-124.
67. Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. Journal of Molecular Biology 2007; 368: 652-665.
68. Carbonell-Estrany X, Simoes EA, Dagan R, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 2010; 125: e35-51.
69. Feltes TF, Sondheimer HM, Tulloh RM, et al. A Randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatric Research 2011; 70: 186-191.
70. Lowry F. FDA Panel Nixes Licensing Request for Motavizumab Medscape News. http://www.medscape.com/viewarticle/722903 [June 3, 2010].
71. Collins PL, Melero JA. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Research 2011; 162: 80-99.
72. Hamelin ME, Couture C, Sackett M, et al. The prophylactic administration of a monoclonal antibody against human metapneumovirus attenuates viral disease and airways hyperresponsiveness in mice. Antiviral Therapy 2008; 13: 39-46.
73. Hamelin ME, Gagnon C, Prince GA, et al. Prophylactic and therapeutic benefits of a monoclonal antibody against the fusion protein of human metapneumovirus in a mouse model. Antiviral Research 2010; 88: 31-37.
74. Deffrasnes C, Hamelin ME, Prince GA, et al. Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus. Antimicrobial Agents and Chemotherapy 2008; 52: 279-287.
75. Roymans D, De Bondt HL, Arnoult E, et al. Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 308-313.
76. Deffrasnes C, Cavanagh MH, Goyette N, et al. Inhibition of human metapneumovirus replication by small interfering RNA. Antiviral Therapy 2008; 13: 821-832.
77. Devincenzo J, Lambkin-Williams R, Wilkinson T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 8800-8805.
78. Fulginiti VA, Eller JJ, Sieber OF, et al. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. American Journal of Epidemiology 1969; 89: 435-448.
79. Kapikian AZ, Mitchell RH, Chanock RM, et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. American Journal of Epidemiology 1969; 89: 405-421.
80. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. American Journal of Epidemiology 1969; 89: 422-434.
81. Openshaw PJ, Culley FJ, Olszewska W. Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine 2001; 20 Suppl 1: S27-31.
82. Moghaddam A, Olszewska W, Wang B, et al. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nature Medicine 2006; 12: 905-907.
83. Delgado MF, Coviello S, Monsalvo AC, et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nature Medicine 2009; 15: 34-41.
84. Ottolini MG, Porter DD, Hemming VG, et al. Enhanced pulmonary pathology in cotton rats upon challenge after immunization with inactivated parainfluenza virus 3 vaccines. Viral Immunology 2000; 13: 231-236.
85. Hamelin ME, Couture C, Sackett MK, et al. Enhanced lung disease and Th2 response following human metapneumovirus infection in mice immunized with the inactivated virus. Journal of General Virology 2007; 88: 3391-3400.
86. Yim KC, Cragin RP, Boukhvalova MS, et al. Human metapneumovirus: enhanced pulmonary disease in cotton rats immunized with formalin-inactivated virus vaccine and challenged. Vaccine 2007; 25: 5034-5040.
87. De Swart RL, Van Den Hoogen BG, Kuiken T, et al. Immunization of macaques with formalin-inactivated human metapneumovirus induces hypersensitivity to hMPV infection. Vaccine 2007; 25: 8518-8528.
88. Katz SL, Milovanovic MV, Enders JF. Propagation of measles virus in cultures of chick embryo cells. Proceedings of the Society for Experimental Biology and Medicine 1958; 97: 23-29.
89. Katz SL, Kempe CH, Black FL, et al. Studies on an attenuated measles-virus vaccine. VIII. General summary and evaluation of the results of vaccine. The New England Journal of Medicine 1960; 263: 180-184.
90. Buynak EB, Hilleman MR. Live attenuated mumps virus vaccine. 1. Vaccine development. Proceedings of the Society for Experimental Biology and Medicine 1966; 123: 768-775.
91. Hilleman MR, Weibel RE, Buynak EB, et al. Live attenuated mumps-virus vaccine. IV. Protective efficacy as measured in a field evaluation. The New England Journal of Medicine 1967; 276: 252-258.
92. Buynak EB, Weibel RE, Whitman JE, et al. Combined live measles, mumps, and rubella virus vaccines. Journal of the American Medical Association 1969; 207: 2259-2262.
93. Hitchner SB, Johnson EP. A virus of low virulence for immunizing fowls against Newcastle disease; avian pneumoencephalitis. Veterinární Medicína 1948; 43: 525-530.
94. Belshe RB, Newman FK, Tsai TF, et al. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old. Journal of Infectious Diseases 2004; 189: 462-470.
95. Wright PF, Karron RA, Belshe RB, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. Journal of Infectious Diseases 2000; 182: 1331-1342.
96. Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization in mothers and infants. The New England Journal of Medicine 2008; 359: 1555-1564.
97. Brideau RJ, Oien NL, Lehman DJ, et al. Protection of cotton rats against human parainfluenza virus type 3 by vaccination with a chimeric FHN subunit glycoprotein. Journal of General Virology 1993; 74(Pt 3): 471-477.
98. Homa FL, Brideau RJ, Lehman DJ, et al. Development of a novel subunit vaccine that protects cotton rats against both human respiratory syncytial virus and human parainfluenza virus type 3. Journal of General Virology 1993; 74(Pt 9): 1995-1999.
99. Lehman DJ, Roof LL, Brideau RJ, et al. Comparison of soluble and secreted forms of human parainfluenza virus type 3 glycoproteins expressed from mammalian and insect cells as subunit vaccines. Journal of General Virology 1993; 74 ( Pt 3): 459-469.
100. Cseke G, Wright DW, Tollefson SJ, et al. Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats. Journal of Virology 2007; 81: 698-707.
101. Swanson KA, Settembre EC, Shaw CA, et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proceedings of the National Academy of Sciences of the United States of America 2011; 108: 9619-9624.
102. NOVAVAX Launches Phase I Clinical Trial to Evaluate its Novel Vaccine Against Respiratory Syncytial Virus (RSV). http://www.novavax.com/download/releases/1-4-11%20RSV%20Phase%201%20trial%20FINAL2.pdf [January 14, 2011].
103. Herfst S, Schrauwen EJ, De Graaf M, et al. Immunogenicity and efficacy of two candidate human metapneumovirus vaccines in cynomolgus macaques. Vaccine 2008; 26: 4224-4230.
104. Walpita P, Flick R. Reverse genetics of negative-stranded RNA viruses: a global perspective. FEMS Microbiology Letters 2005; 244: 9-18.
105. Pelet T, Delenda C, Gubbay O, et al. Partial characterization of a Sendai virus replication promoter and the rule of six. Virology 1996; 224: 405-414.
106. Calain P, Roux L. The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. Journal of Virology 1993; 67: 4822-4830.
107. Durbin AP, Siew JW, Murphy BR, et al. Minimum protein requirements for transcription and RNA replication of a minigenome of human parainfluenza virus type 3 and evaluation of the rule of six. Virology 1997; 234: 74-83.
108. Samal SK, Collins PL. RNA replication by a respiratory syncytial virus RNA analog does not obey the rule of six and retains a nonviral trinucleotide extension at the leader end. Journal of Virology 1996; 70: 5075-5082.
109. Bartlett EJ, Amaro-Carambot E, Surman SR, et al. Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys. Vaccine 2005; 23: 4631-4646.
110. Bartlett EJ, Cruz AM, Esker J, et al. Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates. Journal of Virology 2008; 82: 8965-8977.
111. Bartlett EJ, Castano A, Surman SR, et al. Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes. Virology Journal 2007; 4: 67.
112. Bartlett EJ, Amaro-Carambot E, Surman SR, et al. Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates. Vaccine 2006; 24: 2674-2684.
113. Nolan SM, Skiadopoulos MH, Bradley K, et al. Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates. Vaccine 2007; 25: 6409-6422.
114. Nolan SM, Surman SR, Amaro-Carambot E, et al. Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses. Vaccine 2005; 23: 4765-4774.
115. Skiadopoulos MH, Durbin AP, Tatem JM, et al. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes. Journal of Virology 1998; 72: 1762-1768.
116. Whitehead SS, Firestone CY, Karron RA, et al. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. Journal of Virology 1999; 73: 871-877.
117. Schaap-Nutt A, Scull MA, Schmidt AC, et al. Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeys. Vaccine 2010; 28: 2788-2798.
118. Clements ML, Belshe RB, King J, et al. Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. Journal of Clinical Microbiology 1991; 29: 1175-1182.
119. Lee MS, Greenberg DP, Yeh SH, et al. Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants. Journal of Infectious Diseases 2001; 184: 909-913.
120. Greenberg DP, Walker RE, Lee MS, et al. A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy. Journal of Infectious Diseases 2005; 191: 1116-1122.
121. Schmidt AC, Mcauliffe JM, Huang A, et al. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. Journal of Virology 2000; 74: 8922-8929.
122. Haller AA, Miller T, Mitiku M, et al. Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector. Journal of Virology 2000; 74: 11626-11635.
123. Tang RS, Macphail M, Schickli JH, et al. Parainfluenza virus type 3 expressing the native or soluble fusion (F) protein of respiratory syncytial virus (RSV) confers protection from RSV infection in African green monkeys. Journal of Virology 2004; 78: 11198-11207.
124. Schmidt AC, Wenzke DR, Mcauliffe JM, et al. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. Journal of Virology 2002; 76: 1089-1099.
125. Tang RS, Schickli JH, Macphail M, et al. Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. Journal of Virology 2003; 77: 10819-10828.
126. Tang RS, Spaete RR, Thompson MW, et al. Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults. Vaccine 2008; 26: 6373-6382.
127. Gomez M, Mufson MA, Dubovsky F, et al. Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children. Pediatric Infectious Disease Journal 2009; 28: 655-658.
128. Bernstein DI, Malkin E, Abughali N, et al. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatric Infectious Disease Journal 2012; 31: 109-114.
129. Slobod KS, Shenep JL, Lujan-Zilbermann J, et al. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine 2004; 22: 3182-3186.
130. Jones B, Zhan X, Mishin V, et al. Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV. Vaccine 2009; 27: 1848-1857.
131. Zhan X, Hurwitz JL, Krishnamurthy S, et al. Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B. Vaccine 2007; 25: 8782-8793.
132. Zhan X, Slobod KS, Krishnamurthy S, et al. Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections. Vaccine 2008; 26: 3480-3488.
133. Jones BG, Sealy R, Rudraraju R, et al. Sendai virus-based RSV vaccine protects African green monkeys from RSV infection. Vaccine 2012; 30: 959-968.
134. Nelson CB, Pomeroy BS, Schrall K, et al. An outbreak of conjunctivitis due to Newcastle disease virus (NDV) occurring in poultry workers. American Journal of Public Health and the Nation's Health 1952; 42: 672-678.
135. Bukreyev A, Huang Z, Yang L, et al. Recombinant Newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. Journal of Virology 2005; 79: 13275-13284.
136. Dinapoli JM, Ward JM, Cheng L, et al. Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans. Vaccine 2009; 27: 1530-1539.
137. Teng MN, Whitehead SS, Bermingham A, et al. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. Journal of Virology 2000; 74: 9317-9321.
138. Karron RA, Wright PF, Belshe RB, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. Journal of Infectious Diseases 2005; 191: 1093-1104.
139. Wright PF, Karron RA, Madhi SA, et al. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. Journal of Infectious Diseases 2006; 193: 573-581.
140. Wright PF, Karron RA, Belshe RB, et al. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine 2007; 25: 7372-7378.
141. Biacchesi S, Pham QN, Skiadopoulos MH, et al. Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates. Journal of Virology 2005; 79: 12608-12613.
142. Bao X, Liu T, Shan Y, et al. Human metapneumovirus glycoprotein G inhibits innate immune responses. PLoS Pathogens 2008; 4: e1000077.
143. Ryder AB, Tollefson SJ, Podsiad AB, et al. Soluble recombinant human metapneumovirus G protein is immunogenic but not protective. Vaccine 2010; 28: 4145-4152.
144. Pham QN, Biacchesi S, Skiadopoulos MH, et al. Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo. Journal of Virology 2005; 79: 15114-15122.
145. Biacchesi S, Murphy BR, Collins PL, et al. Frequent frameshift and point mutations in the SH gene of human metapneumovirus passaged in vitro. Journal of Virology 2007; 81: 6057-6067.
146. Schmidt AC. Progress in respiratory virus vaccine development. Seminars in Respiratory and Critical Care Medicine 2011; 32: 527-540.
147. Tang RS, Mahmood K, Macphail M, et al. A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys. Vaccine 2005; 23: 1657-1667.
148. Martinez-Sobrido L, Gitiban N, Fernandez-Sesma A, et al. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. Journal of Virology 2006; 80: 1130-1139.
149. Sawada A, Komase K, Nakayama T. AIK-C measles vaccine expressing fusion protein of respiratory syncytial virus induces protective antibodies in cotton rats. Vaccine 2011; 29: 1481-1490.
150. Mcginnes LW, Gravel KA, Finberg RW, et al. Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. Journal of Virology 2011; 85: 366-377.
151. Mcginnes LW, Pantua H, Laliberte JP, et al. Assembly and biological and immunological properties of Newcastle disease virus-like particles. Journal of Virology 2010; 84: 4513-4523.
152. Fu Y, He J, Zheng X, et al. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice. Biochemical and Biophysical Research Communications 2009; 381: 528-532.
153. Schmidt AC. Progress in respiratory virus vaccine development. Seminars in Respiratory and Critical Care Medicine 2007; 28: 243-252.
154. Bennett JV, Fernandez De Castro J, Valdespino-Gomez JL, et al. Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren. Bulletin of the World Health Organization 2002; 80: 806-812.
155. Durando P, Iudici R, Alicino C, et al. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. Human Vaccines 2011; 7(Suppl): 29-40.
156. Mastelic B, Ahmed S, Egan WM, et al. Mode of action of adjuvants: implications for vaccine safety and design. Biologicals 2010; 38: 594-601.
157. Schmidt AC, Schaap-Nutt A, Bartlett EJ, et al. Progress in the development of human parainfluenza virus vaccines. Expert Review of Respiratory Medicine 2011; 5: 515-526.